CYCN

Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery and development of innovative therapies for serious central nervous system (CNS) disorders. Utilizing its proprietary technology platform, Cyclerion is advancing a promising pipeline of therapeutics designed to address significant unmet medical needs in cognitive impairment and other CNS-related diseases. With a strategic emphasis on enhancing treatment options in the neurotherapeutics space, Cyclerion represents a compelling investment opportunity for institutional investors seeking exposure to breakthrough advancements in the biopharmaceutical sector.